REVISE
-
Principal Investigator
Professor Adam Deane
Project Details
Re-Evaluating the Inhibition of Stress Erosions
Background:
Patients in the Intensive Care Unit (ICU) are at risk for stress-induced gastrointestinal ulceration, which may cause upper gastrointestinal bleeding. Patients frequently receive acid suppressive medication as stress ulcer prophylaxis to prevent gastrointestinal ulceration and bleeding, but whether this improves outcomes that are important to patients is uncertain. Indeed, existing data suggest that stress ulcer prophylaxis may increase the risk of adverse events including death.
To understand whether patients in the ICU should receive stress ulcer prophylaxis, the Re-Evaluating the Inhibition of Stress Erosions (REVISE) trial was conducted. REVISE will enrol 4,800 mechanically ventilated patients to determine the effect of daily pantoprazole administration, as stress ulcer prophylaxis, when compared to placebo, on the primary efficacy outcome of clinically important upper gastrointestinal bleeding, and the primary safety outcome of 90-day all-cause mortality. The hypothesis is that pantoprazole will reduce the number of clinically important gastrointestinal bleeding episodes (primary efficacy outcome) with no difference in mortality (primary safety outcome)
The trial has been completed and will be presented this June at the 2024 Clinical Care Reviews Meeting in Belfast.
Trial Design:
Website
Collaborators
The Global Chair of REVISE is Professor Deborah Cook (McMaster University)
The Chair of the Australian Management Committee is Professor Adam Deane (University of Melbourne)
Funding
National Health and Medical Research Council (NHMRC) Project Grant ($2,955,164)